Cabel - I have modelled a selling price out for my own purposes and came up with 3 different ranges. I do this with most businesses that I get involved with so I have an educated idea of what the potential is under different scenarios. All of these assume  at least 30% RRR is achieved. Low 2 to 6 billion, Medium 6 to 12 billion, High 12 to 25 billion. Each range uses different % RRR, drug price range and market penitration ranges. Also having an effect would be the secondary endpoint results for CKD and cognitive function. The analysts that cover RVX have certainly left themselves lots of room for changes in valuations going forward. IMO it would be very hard to come up with any absolute number before knowing %RRR and effect on secondary end points. 

No matter what, at this point it's just a guess.

All IMO, dyodd.

tada